Illinois Senate Bill 0233 (104th General Assembly) was introduced to amend the Illinois Controlled Substances Act (720 ILCS 570/402) to change penalty classification for knowing possession of fentanyl. The proposal would make possession of 15 grams or more but less than 100 grams of fentanyl a Class 1 felony with a stated imprisonment range of 4 to 15 years. Compliance and legal teams should monitor because it would materially increase criminal exposure and may affect risk controls for entities handling controlled substances (e.g., pharmacies, distributors, healthcare/security procedures) if enacted.
HB0077 proposes amending the Illinois Controlled Substances Act to add xylazine to Schedule III (amending 720 ILCS 570/208 per research text summary) and to create a new exemption section under which xylazine would not be considered a controlled substance in specified legitimate contexts (notably veterinary/FDA-compliant animal drug uses and certain euthanasia/wildlife biologist uses). Compliance teams should monitor because enactment would introduce controlled-substance controls for xylazine outside exempt channels and require organizations to document exemption eligibility for affected activities.
Illinois HB0338 (104th General Assembly) was introduced to amend 720 ILCS 570/101 to make a technical correction to the short title wording of the Illinois Controlled Substances Act. This is a non-substantive/technical drafting fix, but compliance teams tracking statutory citations and legal references may want to monitor it for any downstream impacts on internal legal citations or documentation.
Illinois HB0349 (104th General Assembly) was introduced to amend 720 ILCS 570/101 with a similar technical correction to the short title wording of the Illinois Controlled Substances Act. This is not an enacted change and appears technical, but should be monitored for any changes that affect formal statutory referencing.
HB1038 (104th General Assembly) proposes amendments to 720 ILCS 570/401 and 720 ILCS 570/401.1 to increase fentanyl-related penalties (including reclassification and sentencing changes for certain fentanyl quantities and enhancements when fentanyl is present). The ILGA bill status page shows the most recent action as 2025-01-09 (referred to the House Rules Committee). While not enacted per the provided sources, it remains a relevant proposed change for stakeholders monitoring potential future fentanyl penalty increases under the Illinois Controlled Substances Act.
The ILGA bill status for HB1038 shows the measure proposing fentanyl penalty changes under the Illinois Controlled Substances Act was referred to the House Rules Committee on 2025-01-09. This reflects legislative status activity (not enactment). Compliance teams tracking potential controlled-substance penalty changes should continue monitoring the bill's progress.
Illinois HB1038 (104th General Assembly) proposes amendments to the Illinois Controlled Substances Act increasing penalties for fentanyl-related offenses, including increasing sentencing ranges for manufacture/delivery or possession with intent involving specified quantities of substances containing fentanyl (or analogs) and reclassifying certain weight ranges to higher felony classes. The official bill status shows the bill was referred to the House Rules Committee on 2025-01-09. Compliance teams should monitor as it reflects proposed escalation of fentanyl-related criminal exposure that may influence compliance programs and diversion controls if enacted.
Illinois HB1038 (104th GA) proposes amendments to the Illinois Controlled Substances Act sections addressing manufacture/delivery and trafficking penalties involving fentanyl (and analogs/mixtures). The bill synopsis and text indicate proposed increases to minimum/maximum sentences for specified fentanyl quantities and changes to felony classifications/penalty add-ons when the substance contains fentanyl. Compliance relevance: if enacted, it would materially change the penalty landscape for fentanyl-related offenses under 720 ILCS 570 and may affect compliance risk evaluations and enforcement sensitivity for entities handling controlled substances.
Illinois HB0077 (104th GA) proposes amending the Illinois Controlled Substances Act to schedule xylazine as a Schedule III controlled substance and establish xylazine-specific exemptions (per introduced bill text). Compliance relevance: if enacted, it would add xylazine to Illinois scheduling, changing controlled substance compliance obligations for entities that handle xylazine, with exemptions particularly relevant to veterinary and authorized-use contexts.
The ILGA bill status page for SB0073 (103rd General Assembly) shows a last action of Session Sine Die on 2025-01-07, indicating the prior-session proposal to amend the Illinois Controlled Substances Act for fentanyl-related penalties did not pass in that session. This is a legislative outcome update relevant for compliance tracking and horizon scanning.
IDFPR’s Compliance Capsule reiterates key compliance interpretations under 720 ILCS 570/311.6(e) related to electronic controlled substance prescribing: pharmacists dispensing in good faith on a valid non-electronic prescription may be exempt from discipline; pharmacists are not required to ensure prescriber compliance with e-prescribing mandates; and pharmacies should not refuse to fill a valid prescription solely because it is not electronic. Compliance programs should align pharmacy SOPs, training, and refusal criteria to this clarification to reduce disciplinary risk and patient access issues.